Molecular therapy for pulmonary arterial hypertension: AICAR, an analog of AMP, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 6/April/2015, 17.07

Natural product-based Lifespan extension therapy: Epigallocatechin gallate, the main component of Green tea, increases life span via up regulation of its target gene BubR1, 6/April/2015, 16.47
April 6, 2015
Immune enhancement therapy: AICAR, an analog of AMP, increases SOX2 expression and promotes innate immunity against bacterial infection, 6/April/2015, 17.33
April 6, 2015
Show all

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: AICAR, an analog of AMP, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene. Together, pharmacological formulations encompassing “AICAR or its analogues” may be used to treat pulmonary arterial hypertension.

Amount: $ 500*

Undisclosed information: How AICAR decreases pulmonary arterial hypertension

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Molecular therapy for pulmonary arterial hypertension: AICAR, an analog of AMP, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 6/April/2015,  17.07,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.